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Background: Herpes viruses infection transmitted through healthy but infected blood donors pose a danger to
herpes-naive immunocompromised recipients. The risk of transfusion-related HHV-8 transmission is different in
endemic and not endemic areas. HHV-6 and HHV-8 seroprevalence and viral load among blood donors have been
reported from different countries. The aim of our study was to assess the seroprevalence of HHV-8 and HHV-6 in
volunteer blood donors from Greece which is unknown.
Findings: Serum samples from 179 healthy blood donors were tested for the presence of IgG antibodies against
HHV-6 and HHV-8 with ELISA. None of the 179 donors of Greek origin tested was positive for HHV-8. HHV-6
seropositivity was assessed in 160 blood donors’ samples and was found to be 78.75% (126/160). The HHV-6
seroprevalence did not differ either between males and females or among different decade age groups.
Conclusions: The fact, that no blood donor was positive for HHV-8 IgG antibodies indicates that the risk for transfusion
related HHV-8 transmission in Greece, if any, is negligible and does not warrant broad testing for HHV-8. Definitely
further studies are needed, in order to clarify the potential risk of HHV-6 transmission.
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Introduction
Herpes viruses 6 and 8 (HHV-6 and HHV-8) are enveloped
ds-DNA viruses that can remain latent in the host cells for
a long time. They can re-enter a lytic cycle and thus
cause reactivation of the viral infection. Herpes viruses i
transmitted from healthy but infected blood donors
pose the danger of primary infection to herpes-naive
immunocompromised recipients. HHV-8 seroprevalence
has been assessed in several countries and it is found that
the risk of transfusion-related HHV-8 transmission is
different in endemic and not endemic areas [1]. I HHV-6
seroprevalence among blood donors has also been reported
from different countries [2]. The aim of the present
study was to assess the prevalence of anti- HHV-8
and anti-HHV-6 antibodies in volunteer blood donors
in Greece, which is unknown.* Correspondence: gpanagiotakop@upatras.gr
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unless otherwise stated.Materials and methods
We analyzed 179 blood donor samples collected from
January 2012 to May 2012 in the Blood Bank of Aretaieion
University Hospital, in Athens. All donors completed the
blood donor screening questionnaire and were eligible for
blood donation. Serum samples were stored at −20°C prior
to being tested. The study was approved by the Scientific
and Ethics Committee of our Hospital, and informed
consent was obtained from all participants.
All donors underwent the routine Blood Bank screening
that includes HBsAg testing, antibodies against HIV 1/2,
HCV and HTLV1/2, VDRL (Venereal Disease Research
Laboratory) test, along with Nucleic Acid Testing (NAT)
for HBV, HCV, and HIV. We analyzed the data only
from blood donors, who tested negative for the full above
screening.
The anti-HHV-8 and anti-HHV-6 lytic IgG antibodies
were analysed in serum samples using commercially
available ELISA kits (Advanced Biotechnologies Inc
HHV-8 IgG., Columbia, MD, USA and PANBIO HHV-6
IgG Inverness Medical Innovations Australia), according
to the manufacturer’s instructions.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(IBM Corp, Armonk, NY, USA) P values were considered
as significant when P < 0.05.
Results
The study group comprised of 179 volunteers blood
donors, 136 males and 43 females with a mean age of
38 years (range 19–64 years). All tested negative for
HBV, HCV, HIV1/2, HTLV1/2 and VDRL.
None of the 179 donors of Greek origin tested was
positive for HHV-8. There was only one additional sample
which tested positive for anti-HHV-8 antibodies from one
Greek male donor, who tested positive for HIV (both with
Elisa and NAT) and thus was excluded from the study.
The seroprevalence of HHV6 was assessed in 160 blood
donor samples and was found to be 78.75% (126/160).
There was no significant difference of seropoprevalence
neither between males (77.68%: 94/121) and females
(82.05%: 32/39) nor among different decade age groups
(82.61% group A: 19–30 years old, 81.82% group B: 31–40
years old, 69.76% group C: 41–50 years old, 81.48% group
D: 51–64 years old) (Table 1).
Discussion
Epidemiological data for HHV-6 and HHV-8 in blood
donor in Greece is poor. HHV-8 is the etiological agent
for Kaposi sarcoma, Castelmann’ disease and primaty
effusion lymphoma. Kaposi Sarcoma unrelated to HIV
infection is more common in countries of Mediterranean
“basin” such as Greece and Italy than in Northern Europe
and the USA [3].
The seroprevalence of HHV-8 in blood donors in
Southern Europe ranges from 4.5% (9/200) in Spain
Basque country to 20% and 25% in Sicily and Sardinia
respectively. Interestingly, a seroprevalence of 2.4% was
reported recently in Eastern Sicily [4]. However, the
seroprevelance in blood donors in the U.K. (2.7%) and
the United States (1.4%) is significantly lower [5,6].
Since HHV-8 modes of transmission are elusive and
the HHV-8 transmission through blood transfusion
differs in endemic and non endemic areas, assessing
HHV-8 seroprevalence among blood donors in Greece








Males 37 34 32
Females 9 10 11
Positive cases
38 (82.61%) 36 (81.82%) 30 (69.76%)
p = 0.526 p = 0.668 p = 0.126
*p for each age group was calculated versus the other age groups.related HHV-8 transmission in Greece. We have also
previously found that 48% of the HIV-1-positive and 56%
of the HEPS subjects in Greece tested positive for
anti-HHV-8 antibodies, a prevalence which is higher than
that reported in other countries of Western Europe [7].
All the above mentioned data triggered the study of the
seroprevalence of HHV-8 in healthy blood donors in
Greece. It has been previously reported that the prevalence
of HHV-8 in the general population in Greece is 7.6% and
that the seropositivity for HHV-8 was associated with a
history of endoscopic procedures and HBsAg positivity
[8]. Nevertheless, we found no blood donor tested positive
for HHV-8 IgG antibodies. We have used an ELISA with
similar sensitivity detecting HHV-8 IgG antibodies [9]
with the previous study and thus the discrepancy between
the two studies could be attributed either to the relatively
small size of our study or the differences between the
general population and the blood donors population. We
cannot overlook the fact that with the help of the donor
screening questionnaire we practically exclude candidate
donors with risk factors for HHV-8 transmission.
Endoscopic procedures in the 6 months preceding blood
donation, HBsAg seropositivity, and high-risk sexual
behaviour are exclusion criteria for a blood donor.
In terms of HHV-6, the seroprevalence of HHV-6 in
blood donors in Greece is unknown. Existing literature
deals only with the detection of HHV-6 in the sera or
tissue from patients with certain disease entities [10-14].
We detected HHV-6 IgG antibodies in 78.75% of blood
donors, a seroprevalence similar to the one reported from
other countries. Furthermore, the distribution between
sexes and among age groups confirms the fact that
infection with HHV-6 occurs early in life and that the
IgG antibodies persist for a long time.
Blood transfusion–related transmission of herpesviruses
from chronically infected donors to previously uninfected
or immunocompromised recipients has been a subject
of investigation for several years. The possibility of
transfusion-related transmission of herpesviruses from
healthy adult blood donors is moderately high for HHV-6,
while it seems to be very low for HHV-8 [15].
A number of studies have shown that even in blood






22 (81.48%) 126 (78.75%) 160
P = 0.802
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leukoreduction could efficiently remove HHV-8 from
blood donations, although some authors argue that this
is true only in terms of the viral cellular counterpart.
Cell-free HHV-8 was still present in a ranging percentage
in 42% of subjects after filtration, as 1% to 20% of the total
virus was not removed [16]. Furthermore, it seems that
transfusion with fresh blood from HHV-8 positive blood
donors can be associated with an increased risk of death
[17]. But the fact, that no blood donor was positive for
anti-HHV-8 IgG antibodies indicates that the risk for
HHV-8 transmission with transfusion in Greece, if any, is
negligible and does not warrant broad testing for HHV-8.
Regarding HHV-6 transmission with transfusion, the
natural course of transfused WBCs carrying latent
integrated HHV-6 in a immunocompetent recipient is
the elimination of infected donor cells. However, in
immunodeficient patients, especially those who receive
stem cell transplants, there is an existing possibility that
the integrated virus in the transplanted hematopoietic
cells can be reactivated and lead to acute infection [18].
Although HHV-6 seropositivity reported from several
studies is high, HHV-6 DNA is detected only in a small pro-
portion of seropositive subjects. The possibility of HHV-6
transmission from a healthy blood donor with high HHV-6
viral load to an immunocompromised recipient cannot be
excluded but it does not warrant broad testing for HHV-6.
Further studies are needed, to clarify the potential risk of
HHV-6 transmission from seropositive donors especially
with high HHV-6 viral load but after the adoption of
a common accredited detection method [17].Conclusions
In our study no blood donor tested positive for HHV-8
antibodies and the HHV-8 seroprevalence in the general
population in Greece is not confirmed in our blood donor
population. This may reflect, the usefulness of the donor
screening questionnaire that tends to exclude donors
with risk factors and/or behaviour which are related to
HHV-8 transmission. Accordingly the risk for HHV-8
transmission related to transfusion in Greece, if any, is
substantially low and does not warrant broad testing for
HHV-8. Further studies are needed, in order to clarify the
potential risk of HHV-6 transmission.
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